Long‐term safety and efficacy of the sodium–glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon‐like peptide‐1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52‐week open‐label, multicenter, post‐marketing clinical study

Yasuo Terauchi; Hisataka Fujiwara; Yuji Kurihara; Hideki Suganami; Masahiro Tamura; Masayuki Senda; Ryoji Gunji; Kohei Kaku

doi:10.1111/jdi.13066

Long‐term safety and efficacy of the sodium–glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon‐like peptide‐1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52‐week open‐label, multicenter, post‐marketing clinical study

Journal of Diabetes Investigation ◽

10.1111/jdi.13066 ◽

2019 ◽

Vol 10 (6) ◽

pp. 1518-1526 ◽

Cited By ~ 4

Author(s):

Yasuo Terauchi ◽

Hisataka Fujiwara ◽

Yuji Kurihara ◽

Hideki Suganami ◽

Masahiro Tamura ◽

...

Keyword(s):

Receptor Agonist ◽

Japanese Patients ◽

Open Label ◽

Safety And Efficacy ◽

Sodium Glucose Cotransporter ◽

Post Marketing ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Sodium-glucose cotransporter-2 inhibitor luseogliflozin added to glucagon-like peptide 1 receptor agonist liraglutide improves glycemic control with bodyweight and fat mass reductions in Japanese patients with type 2 diabetes: A 52-week, open-label, singl

Journal of Diabetes Investigation ◽

10.1111/jdi.12694 ◽

2017 ◽

Vol 9 (2) ◽

pp. 332-340 ◽

Cited By ~ 25

Author(s):

Yutaka Seino ◽

Daisuke Yabe ◽

Takashi Sasaki ◽

Atsushi Fukatsu ◽

Hisae Imazeki ◽

...

Keyword(s):

Type 2 Diabetes ◽

Glycemic Control ◽

Fat Mass ◽

Receptor Agonist ◽

Japanese Patients ◽

Open Label ◽

Sodium Glucose Cotransporter ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Efficacy and safety of canagliflozin as add‐on therapy to a glucagon‐like peptide‐1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52‐week, open‐label, phase IV study

Diabetes Obesity and Metabolism ◽

10.1111/dom.13267 ◽

2018 ◽

Vol 20 (7) ◽

pp. 1770-1775 ◽

Cited By ~ 9

Author(s):

Shin‐ichi Harashima ◽

Nobuya Inagaki ◽

Kazuoki Kondo ◽

Nobuko Maruyama ◽

Makiko Otsuka ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Receptor Agonist ◽

Japanese Patients ◽

Efficacy And Safety ◽

Open Label ◽

Open Label Phase ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials

Expert Opinion on Pharmacotherapy ◽

10.1517/14656566.2014.887680 ◽

2014 ◽

Vol 15 (6) ◽

pp. 749-766 ◽

Cited By ~ 51

Author(s):

Yukio Tanizawa ◽

Kohei Kaku ◽

Eiichi Araki ◽

Kazuyuki Tobe ◽

Yasuo Terauchi ◽

...

Keyword(s):

Japanese Patients ◽

Selective Inhibitor ◽

Open Label ◽

Oral Antidiabetic Agents ◽

Antidiabetic Agents ◽

Randomized Controlled ◽

Oral Antidiabetic ◽

Sodium Glucose Cotransporter

Download Full-text

Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes

Journal of Diabetes and its Complications ◽

10.1016/j.jdiacomp.2015.04.004 ◽

2015 ◽

Vol 29 (5) ◽

pp. 670-674 ◽

Cited By ~ 36

Author(s):

Bernt Johan von Scholten ◽

Tine Willum Hansen ◽

Jens Peter Goetze ◽

Frederik Persson ◽

Peter Rossing

Keyword(s):

Type 2 Diabetes ◽

Kidney Function ◽

Receptor Agonist ◽

Term Effect ◽

Long Term Effect ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Long-term safety and efficacy of fasiglifam (TAK-875), a G-protein-coupled receptor 40 agonist, as monotherapy and combination therapy in Japanese patients with type 2 diabetes: a 52-week open-label phase III study

Diabetes Obesity and Metabolism ◽

10.1111/dom.12693 ◽

2016 ◽

Vol 18 (9) ◽

pp. 925-929 ◽

Cited By ~ 33

Author(s):

K. Kaku ◽

K. Enya ◽

R. Nakaya ◽

T. Ohira ◽

R. Matsuno

Keyword(s):

Type 2 Diabetes ◽

Japanese Patients ◽

Phase Iii ◽

Open Label ◽

Safety And Efficacy ◽

Open Label Phase ◽

Phase Iii Study ◽

G Protein Coupled

Download Full-text

Safety and efficacy of long-term treatment with teneligliptin: Interim analysis of a post-marketing surveillance of more than 10,000 Japanese patients with type 2 diabetes mellitus

Expert Opinion on Pharmacotherapy ◽

10.1080/14656566.2017.1420165 ◽

2018 ◽

Vol 19 (2) ◽

pp. 83-91 ◽

Cited By ~ 9

Author(s):

Takashi Kadowaki ◽

Masakazu Haneda ◽

Hiroshi Ito ◽

Makoto Ueno ◽

Miyuki Matsukawa ◽

...

Keyword(s):

Diabetes Mellitus ◽

Interim Analysis ◽

Japanese Patients ◽

Term Treatment ◽

Safety And Efficacy ◽

Post Marketing Surveillance ◽

Long Term Treatment ◽

Post Marketing

Download Full-text

Safety and efficacy of the combination of the glucagon-like peptide-1 receptor agonist liraglutide with an oral antidiabetic drug in Japanese patients with type 2 diabetes: Post-hoc analysis of a randomized, 52-week, open-label, parallel-group trial

Journal of Diabetes Investigation ◽

10.1111/jdi.12759 ◽

2017 ◽

Vol 9 (4) ◽

pp. 831-839 ◽

Cited By ~ 1

Author(s):

Arihiro Kiyosue ◽

Yutaka Seino ◽

Keiji Nishijima ◽

Heidrun Bosch-Traberg ◽

Kohei Kaku

Keyword(s):

Japanese Patients ◽

Open Label ◽

Oral Antidiabetic ◽

Parallel Group ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Post Hoc ◽

Parallel Group Trial ◽

Group Trial

Download Full-text

The safety and efficacy of once-weekly glucagon-like peptide-1 receptor agonist semaglutide in patients with type 2 diabetes mellitus: a systemic review and meta-analysis

Endocrine ◽

10.1007/s12020-018-1708-z ◽

2018 ◽

Vol 62 (3) ◽

pp. 535-545 ◽

Cited By ~ 5

Author(s):

Xuejing Li ◽

Suhui Qie ◽

Xianying Wang ◽

Yingying Zheng ◽

Yang Liu ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Receptor Agonist ◽

Meta Analysis ◽

Systemic Review ◽

Safety And Efficacy ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Insulin secretory defect in familial partial lipodystrophy Type 2 and successful long-term treatment with a glucagon-like peptide 1 receptor agonist

Diabetic Medicine ◽

10.1111/dme.13527 ◽

2017 ◽

Vol 34 (12) ◽

pp. 1792-1794 ◽

Cited By ~ 4

Author(s):

F. Banning ◽

M. Rottenkolber ◽

I. Freibothe ◽

J. Seissler ◽

A. Lechner

Keyword(s):

Receptor Agonist ◽

Term Treatment ◽

Partial Lipodystrophy ◽

Long Term Treatment ◽

Familial Partial Lipodystrophy ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Safety and efficacy of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice: interim results of the STELLA-LONG TERM post-marketing surveillance study

Expert Opinion on Pharmacotherapy ◽

10.1080/14656566.2017.1408792 ◽

2017 ◽

Vol 19 (3) ◽

pp. 189-201 ◽

Cited By ~ 24

Author(s):

Ichiro Nakamura ◽

Hiroshi Maegawa ◽

Kazuyuki Tobe ◽

Hiromi Tabuchi ◽

Satoshi Uno

Keyword(s):

Type 2 Diabetes ◽

Clinical Practice ◽

Real World ◽

Japanese Patients ◽

Surveillance Study ◽

Safety And Efficacy ◽

Post Marketing Surveillance ◽

Post Marketing

Download Full-text